Trial Profile
Safety and Pharmacokinetics of the Novel BACE Inhibitor MK-8931 in Healthy Subjects Following Multiple Dose Administration
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Aug 2012
Price :
$35
*
At a glance
- Drugs Verubecestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 07 Aug 2012 New trial record
- 19 Jul 2012 Results from a pooled analysis presented at the 2012 International Conference on Alzheimer's Disease.